CLINICAL_TRIALS ClinicalTrials.gov record update

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06582017
Title field or adapter rule: {'original_value': 'A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:22.931784+00:00
Published At: 2026-10-20T00:00:00+00:00
Record Updated At: 2026-10-20
Source Retrieved At: 2026-10-31T22:17:52.415050+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Ovarian Cancer", "Pancreas Cancer", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Gastrointestinal Cancer", "Lung Cancer", "Prostate Cancer", "Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-20", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT06582017"
protocolSection.identificationModule.officialTitle: "A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['Phase 1a Dose Escalation in Multiple Myeloma - Part A2', 'Phase 1a Dose Escalation in Solid Tumors - Part A1', 'Phase 1b Dose Expansion in Multiple Myeloma - Part B2', 'Phase 1b Dose Expansion in Solid Tumors - Part B1'], 'description': 'masked immuno-cytokine comprised of an anti-CD138 IgG1 antibody fused to human interferon alpha 2a', 'name': 'QXL138AM Injection every 2 weeks by IV Infusion', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.